Tablet and capsule-format research products.

Oral-format research compounds include AMPK activators, ERR agonists, mitochondrial uncouplers, and lipotropic blend tablets studied in preclinical research models. The Nexus catalog includes 5 oral-format research compounds — examples: BAM15, SLU-PP-332, SLU-PP-332 + BAM15 blend, Lipo-C FAT BLASTER blend, Lipo-C FOCUS blend. Supplied for in-vitro research use only.

Oral tablet and capsule research products use different handling assumptions than vial-format peptide materials. Nexus keeps these products in a separate category so buyers do not apply reconstitution or vial workflow assumptions to tablets and capsules.

This category includes BAM15, SLU-PP-332, SLU-PP-332 + BAM15, Lipo-C Fat Blaster Blend, and Lipo-C Focus Blend. Product pages show format-specific catalog information and variant data.

The oral-format category is structured around product presentation and handling rather than a single pathway. This prevents vial-specific copy, reconstitution recommendations, and solvent cross-sells from appearing where they do not belong.

Nexus still provides the same SEO and catalog scaffolding: product identity, variant price, stock status, lab context where available, and internal links to related records.

Nexus avoids applying injectable-product assumptions to oral-format products. Product records should be reviewed for final SKU, price, and COA status before production launch.

Compounds in this category are oral-format research compounds rather than peptides — supplied as research tablets for laboratory bioavailability research and small-molecule pharmacology research. Common research applications include BAM15 research on mitochondrial uncoupler pharmacology, SLU-PP-332 research on estrogen-related receptor (ERR) agonism, and lipotropic blend research using methionine + inositol + choline (MIC) tablet formats.

The five oral compounds span three mechanism types: mitochondrial uncouplers (BAM15), ERR agonists (SLU-PP-332), and lipotropic blend tablets (Lipo-C fat-blaster blend, Lipo-C focus blend, plus the pre-mixed SLU-PP-332 + BAM15 blend). The category groups compounds primarily by format (oral tablets) rather than by mechanism; mechanism-family categorization places these compounds in Mitochondrial & Energy mechanism family.

Common research-stack pairings: BAM15 + SLU-PP-332 (available as the pre-formulated SLU+BAM blend tablet) for combined mitochondrial-uncoupler-and-ERR-agonist research; BAM15 + AICAR (cross-category) for mitochondrial-uncoupler-plus-AMPK research; SLU-PP-332 + AICAR for ERR-agonist-plus-AMPK research.

Oral-format research tablets are characterized differently than lyophilized peptides — tablet content uniformity is confirmed by assay (typical USP-style dissolution and content uniformity tests). BAM15 (~336 Da) and SLU-PP-332 (~393 Da) are small molecules confirmed by HPLC + MS.